Skip to content

Study · Animal study (in vivo) · rat · 2024

8 results

Activation AMPK in Hypothalamic Paraventricular Nucleus Improves Renovascular Hypertension Through ERK1/2-NF-κB Pathway.

Fu LY, Yang Y, Li RJ, Issotina Zibrila A, Tian H, Jia XY, Qiao JA, Wu JM, Qi J, Yu XJ, Kang YM

Cardiovascular toxicology15 Jul 2024Cited by 4 (Europe PMC)

PMID39008239 (opens in a new tab)DOI10.1007/s12012-024-09888-9 (opens in a new tab)PepBankPUB-39008239
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In renovascular hypertensive rats, AICAR reduced norepinephrine levels.

    In plain wordsIn rats with renovascular hypertension, AICAR reduced norepinephrine levels.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseNorepinephrine level
    Study

    ratn: not reported in source

    Two-kidney, one-clip renovascular hypertension
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    60 μg/day · Bilateral hypothalamic paraventricular nucleus microinjection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats.
    2 context sentences
    Summary · context
    To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM).
    Summary · context
    Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In renovascular hypertensive rats, AICAR reduced systolic blood pressure.

    In plain wordsIn rats with renovascular hypertension, AICAR reduced systolic blood pressure.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseSystolic blood pressure
    Study

    ratn: not reported in source

    Two-kidney, one-clip renovascular hypertension
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    60 μg/day · Bilateral hypothalamic paraventricular nucleus microinjection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats.
    2 context sentences
    Summary · context
    To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM).
    Summary · context
    Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In renovascular hypertensive rats, AICAR increased PVN p-AMPK expression.

    In plain wordsIn rats with renovascular hypertension, AICAR increased brain p-AMPK expression.

    Peptide
    AICAR (acadesine)
    Outcome
    Increasep-AMPK expression
    Study

    ratn: not reported in source

    Two-kidney, one-clip renovascular hypertension
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    60 μg/day · Bilateral hypothalamic paraventricular nucleus microinjection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats.
    2 context sentences
    Summary · context
    To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM).
    Summary · context
    Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In renovascular hypertensive rats, AICAR increased PVN p-AMPK/AMPK.

    In plain wordsIn rats with renovascular hypertension, AICAR increased the ratio of phosphorylated AMPK to total AMPK in the brain.

    Peptide
    AICAR (acadesine)
    Outcome
    Increasep-AMPK/AMPK ratio
    Study

    ratn: not reported in source

    Two-kidney, one-clip renovascular hypertension
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    60 μg/day · Bilateral hypothalamic paraventricular nucleus microinjection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats.
    2 context sentences
    Summary · context
    To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM).
    Summary · context
    Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In renovascular hypertensive rats, AICAR reduced PVN NF-κB p65 activity.

    In plain wordsIn rats with renovascular hypertension, AICAR reduced brain NF-κB p65 activity.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseNF-kappaB p65 activity
    Study

    ratn: not reported in source

    Two-kidney, one-clip renovascular hypertension
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    60 μg/day · Bilateral hypothalamic paraventricular nucleus microinjection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats.
    2 context sentences
    Summary · context
    To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM).
    Summary · context
    Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In renovascular hypertensive rats, AICAR reduced PVN p-ERK1/2 expression.

    In plain wordsIn rats with renovascular hypertension, AICAR reduced brain p-ERK1/2 expression.

    Peptide
    AICAR (acadesine)
    Outcome
    Decreasep-ERK1/2 expression
    Study

    ratn: not reported in source

    Two-kidney, one-clip renovascular hypertension
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    60 μg/day · Bilateral hypothalamic paraventricular nucleus microinjection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats.
    2 context sentences
    Summary · context
    To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM).
    Summary · context
    Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In renovascular hypertensive rats, AICAR reduced PVN p-ERK1/2/ERK1/2.

    In plain wordsIn rats with renovascular hypertension, AICAR reduced the ratio of phosphorylated ERK1/2 to total ERK1/2 in the brain.

    Peptide
    AICAR (acadesine)
    Outcome
    Decreasep-ERK1/2/ERK1/2 ratio
    Study

    ratn: not reported in source

    Two-kidney, one-clip renovascular hypertension
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    60 μg/day · Bilateral hypothalamic paraventricular nucleus microinjection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats.
    2 context sentences
    Summary · context
    To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM).
    Summary · context
    Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In renovascular hypertensive rats, AICAR reduced PVN AT1-R expression.

    In plain wordsIn rats with renovascular hypertension, AICAR reduced brain AT1-R expression.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseAT1-R expression
    Study

    ratn: not reported in source

    Two-kidney, one-clip renovascular hypertension
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    60 μg/day · Bilateral hypothalamic paraventricular nucleus microinjection · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    Four weeks of bilateral PVN injection of AMPK activator AICAR, attenuated the NE level and SBP, increased the expression of p-AMPK and p-AMPK/AMPK, lessened the NF-κB p65 activity, decreased the expression of p-ERK1/2, p-ERK1/2/ERK1/2 and AT1-R in the PVN of 2K1C rats.
    2 context sentences
    Summary · context
    To examine this hypothesis, we employed a renovascular hypertensive animal model developed via two-kidney, one-clip (2K1C) and sham-operated (SHAM).
    Summary · context
    Artificial cerebrospinal fluid (aCSF), used as vehicle, or 5-amino-1-β-D-ribofuranosyl-imidazole-4-carboxamide (AICAR, an AMPK activator, 60 μg/day) was microinjected bilaterally in the PVN of these rats for 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.